JP2022504866A - トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法 - Google Patents
トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法 Download PDFInfo
- Publication number
- JP2022504866A JP2022504866A JP2021520348A JP2021520348A JP2022504866A JP 2022504866 A JP2022504866 A JP 2022504866A JP 2021520348 A JP2021520348 A JP 2021520348A JP 2021520348 A JP2021520348 A JP 2021520348A JP 2022504866 A JP2022504866 A JP 2022504866A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- trastuzumab
- therapy
- adjuvant
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001612 trastuzumab emtansine Drugs 0.000 title claims abstract description 228
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 73
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 193
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 79
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 77
- 229960000575 trastuzumab Drugs 0.000 claims description 188
- 238000009098 adjuvant therapy Methods 0.000 claims description 157
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 116
- 238000011282 treatment Methods 0.000 claims description 114
- 201000010099 disease Diseases 0.000 claims description 113
- 206010028980 Neoplasm Diseases 0.000 claims description 109
- 230000003902 lesion Effects 0.000 claims description 82
- 238000011460 HER2-targeted therapy Methods 0.000 claims description 80
- 210000001165 lymph node Anatomy 0.000 claims description 72
- 229940123237 Taxane Drugs 0.000 claims description 70
- 238000009099 neoadjuvant therapy Methods 0.000 claims description 68
- 201000011510 cancer Diseases 0.000 claims description 67
- 230000004083 survival effect Effects 0.000 claims description 65
- 239000003814 drug Substances 0.000 claims description 62
- 210000000481 breast Anatomy 0.000 claims description 60
- 230000009467 reduction Effects 0.000 claims description 58
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 57
- 229940079593 drug Drugs 0.000 claims description 53
- 238000011470 radical surgery Methods 0.000 claims description 45
- 238000002512 chemotherapy Methods 0.000 claims description 40
- 230000009885 systemic effect Effects 0.000 claims description 34
- 239000002671 adjuvant Substances 0.000 claims description 31
- 230000001575 pathological effect Effects 0.000 claims description 29
- 229960002087 pertuzumab Drugs 0.000 claims description 25
- 238000001802 infusion Methods 0.000 claims description 24
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 24
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 23
- 229960004891 lapatinib Drugs 0.000 claims description 22
- 229950008835 neratinib Drugs 0.000 claims description 21
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims description 20
- 229960001686 afatinib Drugs 0.000 claims description 19
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 19
- 229950002205 dacomitinib Drugs 0.000 claims description 19
- 238000009097 single-agent therapy Methods 0.000 claims description 18
- 238000009121 systemic therapy Methods 0.000 claims description 15
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 238000009104 chemotherapy regimen Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 3
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract description 6
- 239000000611 antibody drug conjugate Substances 0.000 abstract description 5
- 238000010586 diagram Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 description 33
- 238000001990 intravenous administration Methods 0.000 description 28
- 238000001356 surgical procedure Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 21
- 230000034994 death Effects 0.000 description 19
- 231100000517 death Toxicity 0.000 description 19
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 18
- 208000030776 invasive breast carcinoma Diseases 0.000 description 13
- 238000002271 resection Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 108091008039 hormone receptors Proteins 0.000 description 12
- 229960005558 mertansine Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000003447 ipsilateral effect Effects 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 229940127557 pharmaceutical product Drugs 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 238000007901 in situ hybridization Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 102000001301 EGF receptor Human genes 0.000 description 8
- 108060006698 EGF receptor Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 238000011498 curative surgery Methods 0.000 description 8
- 102000015694 estrogen receptors Human genes 0.000 description 8
- 108010038795 estrogen receptors Proteins 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 102000003998 progesterone receptors Human genes 0.000 description 8
- 108090000468 progesterone receptors Proteins 0.000 description 8
- 210000005005 sentinel lymph node Anatomy 0.000 description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 238000003364 immunohistochemistry Methods 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 229940045799 anthracyclines and related substance Drugs 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 206010061819 Disease recurrence Diseases 0.000 description 5
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 5
- 241000711549 Hepacivirus C Species 0.000 description 5
- 229930126263 Maytansine Natural products 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000001099 axilla Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940022353 herceptin Drugs 0.000 description 5
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 5
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000009458 Carcinoma in Situ Diseases 0.000 description 4
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 4
- 108090000340 Transaminases Proteins 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003433 contraceptive agent Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- -1 flow promoters Substances 0.000 description 4
- 201000004933 in situ carcinoma Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000009115 maintenance therapy Methods 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002254 contraceptive effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000011521 systemic chemotherapy Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000000779 thoracic wall Anatomy 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004010 HER dimerization inhibitor Substances 0.000 description 2
- 101150054472 HER2 gene Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 108700020302 erbB-2 Genes Proteins 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000011368 intensive chemotherapy Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 238000009810 tubal ligation Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VXZCUHNJXSIJIM-MEBGWEOYSA-N (z)-but-2-enedioic acid;(e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound OC(=O)\C=C/C(O)=O.C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 VXZCUHNJXSIJIM-MEBGWEOYSA-N 0.000 description 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010264 Condition aggravated Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010066896 HER-2 positive gastric cancer Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 241000417247 Homotherium serum Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 206010051081 Nodular regenerative hyperplasia Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960001320 lapatinib ditosylate Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229950001474 maitansine Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000006000 skin carcinoma in situ Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000037960 stage I uterine cancer Diseases 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本出願は、2018年10月15日に出願された米国特許仮出願第62/745,914号の利益を主張するものであり、その開示は参照によりその全体が本明細書に組み込まれている。
I. 定義、
II. トラスツズマブ エムタンシン、
III.トラスツズマブ エムタンシンの製剤、
IV. トラスツズマブ エムタンシンの投与、
V. 製品、
VI. 例示的な実施形態。
を有し、式中、Trは、リンカー部分MCCを介してマイタンシノイド薬物部分DM1に連結されたトラスツズマブである(米国特許第5208020号、同6441163号)。微小管阻害薬マイタンシノイドDM1は、マイタンシノイドのマイタンシノールから合成され、ヘテロ二官能性試薬SMCCを用いて抗体のリシン残基に主に連結されている。薬物の抗体に対する比又は薬物搭載量は、トラスツズマブ エムタンシン(トラスツズマブ-MCC-DM1)の上記構造においてpで表され、整数値1~約8の範囲にある。トラスツズマブ-MCC-DM1は、1個、2個、3個、4個、5個、6個、7個、及び8個の薬物部分が抗体トラスツズマブに共有結合している、様々に搭載かつ結合された抗体-薬物複合体のすべての混合物を含む(米国特許第7097840号、米国特許出願公開第2005/0276812号、同2005/0166993号)。平均して、トラスツズマブ エムタンシンは、3.5 DM1分子/抗体を含有する。
A9。患者が、成人患者である、A~A8のいずれか1つに記載の上述の方法。
(i)根治手術によって乳房及び腋窩リンパ節内の臨床的に明らかなすべての腫瘍細胞を除去することと、
(ii)当該患者に、トラスツズマブ エムタンシン(T-DM1)を用いる単独療法のアジュバント療法を行うことと、を含む、方法、を提供する。
1.HER2陽性乳癌。HER2陽性状態は、治療前生検材料に基づき、3+の免疫組織化学(IHC)スコアとして、及び/又は試験登録前に中央検査機関により将来を見越して(prospectively)確認されたインサイツハイブリダイゼーション(ISH)により陽性として定義される。ISH陽性は、17番染色体コピーのシグナル数に対するHER2遺伝子コピー数について≧2.0の比として定義される。ホルマリン固定パラフィン包埋腫瘍組織ブロック又は部分ブロックは、HER2発現の中央判定のために利用可能である必要がある。サイトが現地の規則のために組織ブロックを送付できない場合、少なくとも8枚の未染色スライドをHER2試験のために送付し、追加で最大5枚のスライドを探索的バイオマーカー研究のために送付すべきである。中央検査機関は、IHC及びISHアッセイの両方を実施するが、一方の陽性結果のみが適格性のために必要である。治療前生検からの十分な材料が申請のために得られない場合には、適格性についての中央HER2判定は、根治手術の時点からの残存腫瘍組織について実施することができる。同時性両側浸潤性疾患を有する患者は、両方の病変がHER2陽性である場合に適格である。
a.絶対好中球数≧1200細胞/mm3
b.血小板数≧100000細胞/mm3
c.ヘモグロビン≧9.0g/dL。このレベルを得るために患者は赤血球輸血を受けてもよい
d.血清クレアチニン<1.5×正常上限(ULN)
e.国際標準比(INR)及び活性化部分トロンボプラスチン時間(aPTT)≦1.5×ULN
f.血清AST及びALT≦1.5×ULN
g.血清総ビリルビン(TBILI)≦1.0×ULN(正常範囲内)、ジルベール症候群を有する患者を除く、その患者について直接ビリルビンは、正常範囲内でなければならない。
h.血清アルカリホスファターゼ(ALK)≦1.5×ULN
i.ネオアジュバント化学療法を受けた後にECHO又はMUGAについてスクリーニングLVEF≧50%であり、事前化学療法LVEFから15%超の絶対点までLVEFの減少なし。又は、事前化学療法LVEFが評価されていなかった場合、スクリーニングLVEFは、ネオアジュバント化学療法の完了後に55%以上である必要がある。
a.禁欲は、患者の好ましい通常の生活様式に合致する場合にのみ許容される。周期的な禁欲(例えば、カレンダー法、排卵法、症候体温法、又は排卵後法)及び中絶性交は、許容される避妊方法ではない。失敗率が1年当たり1%未満の避妊法の例としては、卵管結紮術、男性不妊手術、ホルモンインプラント、組み合わせた経口又は注入ホルモン避妊薬の確立された適切な使用、及びある特定の子宮内器具が挙げられる。あるいは、2つの方法(例えば、コンドーム及び子宮頸管キャップなどの2つのバリア式方法)を組み合わせて、1年当たり1%未満の失敗率を達成することができる。バリア式方法は、常に殺精子剤の使用を追加する必要がある。
b.パートナーが妊娠している男性患者は、コンドームを使うか、又は妊娠期間にわたり性的行為を真に慎む必要がある。
疾患関連除外基準:
ドキソルビシン>240mg/m2。
エピルビシン又はドキソルビシン塩酸塩内包リポソーム(Myocet(登録商標))>480mg/m2。
他のアントラサイクリンについて、ドキソルビシン>240mg/m2と等価の曝露。
a.NCI CTCAE(バージョン4.0)グレード≧3の症候性CHF又はNYHA診断基準分類≧IIの病歴。
b.抗狭心症薬を必要とする狭心症、十分な投薬によって制御されない重篤心不整脈、重症伝導異常、又は臨床的に有意な弁膜症。
c.高リスクのコントロール不良不整脈。すなわち、安静時心拍数が100/分を超える心房頻拍、重大な心室性不整脈(心室頻拍)、又は高度房室ブロック(第II度房室ブロックタイプ2[Mobitz2]又は第III度房室ブロック)。
d.術前療法を受けている間又は受けて以来の、左心室機能不全、心不整脈、又は心虚血に関連する重大な症状(グレード≧2)。
e.(例えば、術前療法中の)事前トラスツズマブ治療で<40%へのLVEFの減少履歴
f.コントロール不良高血圧(収縮期血圧>180mmHg、かつ/又は拡張期血圧>100mmHg)。
g.持続的酸素療法のためのECG要件における貫壁性梗塞のエビデンス
A群:トラスツズマブ エムタンシン3.6mg/kg、IV、q3wで14サイクル投与。
B群:トラスツズマブ6mg/kg、IV、q3wで14サイクル投与(トラスツズマブの前回の投与以来6週超の間隔があった場合、8mg/kgの負荷用量を投与すべきである)。
・診察(presentation)時にホルモン受容体陽性疾患を有する患者においては、ホルモン療法(アロマターゼ阻害薬、タモキシフェンなど)を開始すべきである。
・乳房温存手術を受けている患者については、全乳房照射が必要とされる。現地のポリシーに従い原発腫瘍床ブーストを行うことができる。初期診断において、患者に臨床的T3(T3N0を除く)若しくはT4疾患、及び/又は臨床的N2若しくはN3疾患が見出された場合は、局所リンパ節照射が必要である。T3N0の場合又はリンパ節において残存病変がある場合には、局所リンパ節照射が推奨される。
・乳房切除後の患者については、初期診断において、患者に臨床的T3(T3N0を除く)若しくはT4疾患、及び/又は臨床的N2若しくはN3疾患が見出された場合は、胸壁照射及び局所リンパ節照射が必要である。T3N0の場合又はリンパ節において残存病変がある場合には、胸壁照射及び局所リンパ節照射が推奨される。これらの基準を満たさない乳房切除後の患者については、施設の基準に基づき、治験責任医師の裁量で放射線療法を行う。
・診察時の臨床的病期:手術不可能(病期T4NxM0又はTxN2-3M0)対手術可能(病期T1-3N0-1M0)
・ホルモン受容体の状態:エストロゲン受容体(ER)又はプロゲステロン受容体(PgR)陽性対、ER及びPgR陰性/不明
・術前HER2標的療法:トラスツズマブ対トラスツズマブ+付加的なHER2標的薬(複数可)
・術前療法後に評価した病理学的なリンパ節の状態:リンパ節陽性対リンパ節陰性/未実施
・同側浸潤性乳房腫瘍再発(すなわち、元の原発巣と同じ乳房実質に及ぶ浸潤性乳癌)。
・同側限局性-局所浸潤性乳癌再発(すなわち、腋窩、局所リンパ節、胸壁、及び/又は同側乳房の皮膚における浸潤性乳癌)。
・遠隔再発(すなわち、組織学的に再発性の浸潤性乳癌と確認されたか、又は臨床的に再発性の浸潤性乳癌と診断された、上述の2つの部位以外の、いずれかの解剖学的部位における乳癌のエビデンス)。
・対側浸潤性乳癌。
・乳癌、非乳房癌、又は
既知ではない原因を含むなんらかの原因による死亡(しかしながら、できる限り死亡原因は特定されるべきである。)。
・一次エンドポイントについてのIDFSと同様に定義されるが、事象として二次原発非乳房浸潤性の癌を含む(任意の部位における非黒色腫皮膚癌及び上皮内癌[CIS]を除く)、二次原発非乳房癌を含むIDFS
・DFS:無作為割付けと、二次原発非乳房癌事象を含むIDFS事象、又は対側若しくは同側腺管上皮内癌(DCIS)が最初に生じた日との間の時間として定義される
・OS:無作為割付けからなんらかの原因による死までの時間として定義される
・DRFI:無作為割付けと、遠隔乳癌再発の日との間の時間として定義される
・NCI CTCAE(バージョン4.0)に基づくすべてのAEの発生率、種類、及び重症度。
・SAEの発生率、種類、及び重症度。
・投与の中断、変更、又は延期につながるAEの発生率及び種類。
・試験における死亡原因。
・異常な臨床検査値。
・LVEFの減少。
・心臓性事象、心臓性の原因による死亡、又はベースラインから、<50%のLVEFへの、≧10パーセントのLVEFの減少を伴う重症CHF(NYHA分類III又はIV)として定義される。
・治療に関連する症状の発生率、及びEORTC QLQ-C30質問票、及びQLQBR23モジュールを用いて評価した、健康関連の生活の質(HRQOL)の評価。
・ヘルス・エコノミック・モデリングに関するEuroQol EQ-5D(商標)質問票を用いて評価した、健康状態の評価。
Cortazar P,Zhang L,Untch M,et al.Pathological complete response and long-term clinical benefit in breast cancer:the CTNeoBC pooled analysis.Lancet 2014;384:164-72.
de Azambuja E,Holmes AP,Piccart-Gebhart M,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):survival outcomes of a randomised,open-label,multicentre,phase 3 trial and their association with pathological complete response.Lancet Oncol 2014;15:1137-46.
Dieras V,Miles D,Verma S,et al.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer(EMILIA):a descriptive analysis of final overall survival results from a randomised,open-label,phase 3 trial.Lancet Oncol 2017;18:732-742.
Dieras V,Harbeck N,Budd GT,et al.Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer:an integrated safety analysis.J Clin Oncol.2014;32(25):2750-2757.
Egloff H,Kidwell KM,Schott A.Ado-trastuzumab emtansine-induced pulmonary toxicity:a single-institution retrospective review.Case Rep Oncol.2018 11:527-533.
Gianni L,Eiermann W,Semiglazov V,et al.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer(NOAH):follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.Lancet Oncol 2014;15:640-7.
Gianni L,Pienkowski T,Im YH,et al.5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced,inflammatory,or early-stage HER2-positive breast cancer(NeoSphere):a multicentre,open-label,phase 2 randomised trial.Lancet Oncol 2016;17:791-800.
Gullo G,Walsh N,Fennelly D,et al.Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer:the “one thousand HER2 patients” project.Br J Cancer 2018;119:374-380.
Hudis CA,Barlow WE,Costantino JP,et al.Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials:the STEEP system.J Clin Oncol 2007;25:2127-32.
Hurvitz SA,Martin M,Symmans WF,et al.Neoadjuvant trastuzumab,pertuzumab,and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer(KRISTINE):a randomised,open-label,multicentre,phase 3 trial.Lancet Oncol 2018;19:115-126.
Junttila TT,Li G,Parsons K,Phillips GL,et al.Trastuzumab-DM1(T-DM1)retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.Breast Cancer Res Treat 2011;128:347-56.
Kadcyla(添付文書).South San Francisco,CA:Genentech,Inc.;September 2018.
Krop IE,Kim SB,Gonzalez-Martin A,et al.Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer(TH3RESA):a randomised,open-label,phase 3 trial.Lancet Oncol 2014;15:689-99.
Krop IE,Kim SB,Martin AG,et al.Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer(TH3RESA):final overall survival results from a randomised open-label phase 3 trial.Lancet Oncol 2017;18:743-754.
Krop IE,Suter TM,Dang CT,et al.Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.J Clin Oncol 2015;33:1136-42.
Lewis Phillips GD,Li G,Dugger DL,et al.Targeting HER2-positive breast cancer with trastuzumab-DM1,an antibody-cytotoxic drug conjugate.Cancer Res 2008;68:9280-90.
Lindstrom LS,Karlsson E,Wilking UM,et al.Clinically used breast cancer markers such as estrogen receptor,progesterone receptor,and human epidermal growth factor receptor 2 are unstable throughout tumor progression.J Clin Oncol 2012;30:2601-2608.
Martin M,Holmes FA,Ejlertsen B,et al.Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer(ExteNET):5-year analysis of a randomised,double-blind,placebo-controlled,phase 3 trial.Lancet Oncol 2017;18:1688-1700.
Masuda N,Lee SJ,Ohtani S,et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy.N Engl J Med 2017;376:2147-2159.
National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology:breast cancer version 1.2018.
Perez EA,Barrios C,Eiermann W,et al.Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive,advanced breast cancer:primary results from the phase III MARIANNE study.J Clin Oncol 2017;35:141-148.
Promberger R,Dubsky P,Mittlbock M,et al.Postoperative CMF does not ameliorate poor outcomes in women with residual invasive breast cancer after neoadjuvant epirubicin/docetaxel chemotherapy.Clin Breast Cancer 2015;15:505-11.
Schneeweiss A,Chia S,Hickish T,et al.Long-term efficacy analysis of the randomised,phase II TRYPHAENA cardiac safety study:Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.Eur J Cancer 2018;89:27-35.
Senkus E,Kyriakides S,Ohno S,et al.Primary breast cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up.Ann Oncol 2015;26(Suppl 5):v8-30.
Untch M,Fasching PA,Konecny GE,et al.Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer:results from the TECHNO trial of the AGO and GBG study groups.J Clin Oncol 2011;29:3351-7.
Verma S,Miles D,Gianni L,et al.Trastuzumab emtansine for HER2-positive advanced breast cancer.N Engl J Med 2012;367:1783-91.
von Minckwitz G,Procter M,de Azambuja E,et al.Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.N Engl J Med 2017;377:122-131.
Yoshida A,Hayashi N,Suzuki K,Takimoto M,Nakamura S,Yamauchi H.Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer.J Surg Oncol 2017;116:1021-1028.
von Minckwitz G,et al.,Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.N Engl J Med 2019:380:617-628.
Claims (78)
- HER2陽性早期乳癌を有する患者に、単独療法として有効量のトラスツズマブ エムタンシン(T-DM1)を投与することを含むアジュバント療法の方法であって、前記患者が、術前全身治療後に残存病変を有する、方法。
- 前記残存病変が、乳房に存在する、請求項1に記載の方法。
- 前記残存病変が、リンパ節に存在する、請求項1に記載の方法。
- 前記残存病変が、乳房及びリンパ節に存在する、請求項1に記載の方法。
- 前記術前全身治療が、HER2標的療法を含む、請求項1~4のいずれか一項に記載の方法。
- 前記HER2標的療法が、トラスツズマブを含む、請求項5に記載の方法。
- 前記HER2標的療法が、ペルツズマブを更に含む、請求項6に記載の方法。
- 前記HER2標的療法が、ラパチニブ、ネラチニブ、ダコミチニブ、アファチニブ及びそれらの組み合わせからなる群から選択される薬剤を更に含む、請求項5又は6に記載の方法。
- 前記術前全身治療が、タキサンを更に含む、請求項5~8のいずれかに記載の方法。
- 前記患者が、成人患者である、請求項1~9のいずれかに記載の方法。
- 前記患者が、T-DM1の前記投与前に根治手術を受ける、請求項1~10のいずれかに記載の方法。
- 前記患者が、前記根治手術後12週以内にT-DM1を投与される、請求項11に記載の方法。
- 前記患者が、少なくとも16週の、タキサン含有化学療法レジメン及びHER2標的療法を用いる術前全身治療を完了している、請求項1~12のいずれかに記載の方法。
- 前記患者が、少なくとも6サイクルのタキサン含有化学療法を完了している、請求項1~13のいずれか一項に記載の方法。
- 前記患者が、3週ごとに3.6mg/kgの用量でT-DM1を投与される、請求項1~14のいずれか一項に記載の方法。
- 前記患者が、3週ごとに3.6mg/kgの用量で14サイクルにわたりT-DM1を投与される、請求項1~15のいずれか一項に記載の方法。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、無浸潤疾患生存期間(IDFS)を実質的に増加させる、請求項1~16のいずれか一項に記載の方法。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、浸潤性疾患再発のリスクの50%低減をもたらす、請求項1~17のいずれか一項に記載の方法。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、遠隔再発の減少をもたらす、請求項1~18のいずれか一項に記載の方法。
- 前記アジュバント療法が、アジュバントトラスツズマブと比較して、遠隔再発のリスクの40%低減をもたらす、請求項1~19のいずれか一項に記載の方法。
- 患者のHER2陽性早期乳癌のアジュバント療法における使用のためのトラスツズマブ エムタンシン(T-DM1)であって、前記アジュバントが、単独療法であり、かつ前記患者が、術前全身治療後に残存病変を有する、使用のためのトラスツズマブ エムタンシン(T-DM1)。
- 前記残存病変が、乳房に存在する、リンパ節に存在する、又は乳房及びリンパ節に存在する、請求項21に記載の使用のためのT-DM1。
- 前記術前全身治療が、HER2標的療法を含む、請求項21又は22に記載の使用のためのT-DM1。
- 前記HER2標的療法が、トラスツズマブ又はトラスツズマブ並びにペルツズマブ、ラパチニブ、ネラチニブ、ダコミチニブ及び/若しくはアファチニブを含む、請求項23に記載の使用のためのT-DM1。
- 前記術前全身治療が、タキサンを更に含む、請求項21~25のいずれかに記載の使用のためのT-DM1。
- 前記患者が、成人患者である、請求項21~25のいずれかに記載の使用のためのT-DM1。
- 前記患者が、T-DM1の投与前に根治手術を受ける、請求項21~26のいずれかに記載の使用のためのT-DM1。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、無浸潤疾患生存期間(IDFS)を実質的に増加させる、請求項21~27のいずれかに記載の使用のためのT-DM1。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、浸潤性疾患再発のリスクの50%低減をもたらす、請求項21~28のいずれかに記載の使用のためのT-DM1。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、遠隔再発の減少をもたらす、請求項21~29のいずれかに記載の使用のためのT-DM1。
- 前記アジュバント療法が、アジュバントトラスツズマブと比較して、遠隔再発のリスクの40%低減をもたらす、請求項21~30のいずれかに記載の使用のためのT-DM1。
- 患者のHER2陽性早期乳癌のアジュバント療法に使用するための医薬の製造におけるトラスツズマブ エムタンシン(T-DM1)の使用であって、前記アジュバントが、単独療法であり、前記患者が、術前全身治療後に残存病変を有する、使用。
- 前記残存病変が、乳房に存在する、リンパ節に存在する、又は乳房及びリンパ節に存在する、請求項32に記載の使用。
- 前記術前全身治療が、HER2標的療法を含む、請求項32又は33に記載の使用。
- 前記HER2標的療法が、トラスツズマブ又はトラスツズマブ並びにペルツズマブ、ラパチニブ、ネラチニブ、ダコミチニブ及び/若しくはアファチニブを含む、請求項34に記載の使用。
- 前記術前全身治療が、タキサンを更に含む、請求項32~35のいずれかに記載の使用。
- 前記患者が、成人患者である、請求項32~36のいずれかに記載の使用。
- 前記患者が、T-DM1の投与前に根治手術を受ける、請求項32~37のいずれかに記載の使用。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、無浸潤疾患生存期間(IDFS)を実質的に増加させる、請求項32~38のいずれかに記載の使用。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、浸潤性疾患再発のリスクの50%低減をもたらす、請求項32~39のいずれかに記載の使用。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、遠隔再発の減少をもたらす、請求項32~40のいずれかに記載の使用。
- 前記アジュバント療法が、アジュバントトラスツズマブと比較して、遠隔再発のリスクの40%低減をもたらす、請求項32~41のいずれかに記載の使用。
- HER2陽性早期乳癌を有する患者において乳癌を治療するための方法であって、前記患者が、化学療法及びHER2標的療法を用いるネオアジュバント療法後に乳房又は腋窩リンパ節内に残存病変を有する方法であって、
(i)根治手術によって前記乳房及び前記腋窩リンパ節内の臨床的に明らかなすべての腫瘍細胞を除去することと、
(ii)前記患者に、トラスツズマブ エムタンシン(T-DM1)を用いる単独療法のアジュバント療法を行うことと、を含む、方法。 - 前記患者が、タキサン及びHER2標的療法を用いるネオアジュバント療法後に前記乳房又は前記腋窩リンパ節内に残存病変を有する、請求項44に記載の方法。
- 前記患者が、少なくとも16週の、タキサン含有化学療法を用いるネオアジュバント療法を完了している、請求項44又は45のいずれか一項に記載の方法。
- 前記患者が、少なくとも6サイクルのタキサン含有化学療法を完了している、請求項44~46のいずれか一項に記載の方法。
- 前記患者が、根治手術後12週以内にT-DM1を用いるアジュバント治療を受ける、請求項44~47のいずれか一項に記載の方法。
- 前記患者が、3週ごとに3.6mg/kgの用量でT-DM1を注入するアジュバント治療を受ける、請求項44~48のいずれか一項に記載の方法。
- 前記患者が、3週ごとに3.6mg/kgの用量で14サイクルにわたりT-DM1を注入するアジュバント治療を受ける、請求項44~49のいずれか一項に記載の方法。
- 前記治療が、トラスツズマブを用いるアジュバント治療と比較して、無浸潤疾患生存期間(IDFS)を実質的に増加させる、請求項44~50のいずれか一項に記載の方法。
- 前記治療が、トラスツズマブを用いるアジュバント治療と比較して、遠隔再発の減少をもたらす、請求項44~51のいずれか一項に記載の方法。
- ネオアジュバント療法後に残存病変を有する患者におけるHER2陽性早期乳癌の治療のための方法であって、前記方法が、前記患者が根治手術を受けた後に、前記患者に有効量のトラスツズマブ エムタンシン(T-DM1)を投与することを含む、方法。
- 前記残存病変が、病理学的残存浸潤性疾患である、請求項53に記載の方法。
- 前記残存病変が、リンパ節内の病理学的残存浸潤性疾患である、請求項53又は54に記載の方法。
- 前記残存病変が、乳房内の病理学的残存浸潤性疾患である、請求項53~55のいずれか一項に記載の方法。
- 前記方法が、化学療法を用いる事前の又は同時のアジュバント治療を含まない、請求項53~56のいずれか一項に記載の方法。
- 前記ネオアジュバント療法が、タキサン及びHER2標的療法を含む、請求項53~57のいずれか一項に記載の方法。
- 前記ネオアジュバント療法が、タキサン及びトラスツズマブを含む、請求項53~58のいずれか一項に記載の方法。
- 前記患者が、少なくとも16週のネオアジュバント療法を完了している、請求項53~59のいずれか一項に記載の方法。
- 前記患者が、少なくとも6サイクルのタキサン含有ネオアジュバント療法を完了している、請求項53~60のいずれか一項に記載の方法。
- 前記患者が、根治手術後12週以内にT-DM1を用いる治療を受ける、請求項53~61のいずれか一項に記載の方法。
- 前記患者が、3週ごとに3.6mg/kgの用量でT-DM1を注入する治療を受ける、請求項53~62のいずれか一項に記載の方法。
- 前記患者が、3週ごとに3.6mg/kgの用量で14サイクルにわたりT-DM1を注入する治療を受ける、請求項53~63のいずれか一項に記載の方法。
- 前記治療が、トラスツズマブを用いるアジュバント治療と比較して、無浸潤疾患生存期間(IDFS)を実質的に増加させる、請求項53~64のいずれか一項に記載の方法。
- 前記治療が、トラスツズマブを用いるアジュバント治療と比較して、遠隔再発の減少をもたらす、請求項53~65のいずれか一項に記載の方法。
- HER2陽性早期乳癌を有する患者において、癌再発のリスクを低減するための方法であって、前記方法が、前記患者に有効量のトラスツズマブ エムタンシン(T-DM1)を投与することを含み、前記患者が、ネオアジュバント療法により病理学的な完全寛解を達成しておらず、かつ前記患者が、T-DM1の前記投与前に根治手術を受けている、方法。
- 前記方法が、化学療法を用いる事前の又は同時のアジュバント治療を含まない、請求項67に記載の方法。
- 前記ネオアジュバント療法が、タキサン及びHER2標的療法を含む、請求項67又は68に記載の方法。
- 前記ネオアジュバント療法が、タキサン含有化学療法レジメン及びトラスツズマブを含む、請求項67~69のいずれか一項に記載の方法。
- 前記患者が、少なくとも16週のネオアジュバント療法を完了している、請求項67~70のいずれか一項に記載の方法。
- 前記患者が、少なくとも6サイクルのタキサン含有ネオアジュバント療法を完了している、請求項67~71のいずれか一項に記載の方法。
- 前記患者が、根治手術後12週以内にT-DM1を用いる治療を受ける、請求項67~72のいずれか一項に記載の方法。
- 前記患者が、3週ごとに3.6mg/kgの用量でT-DM1を注入する治療を受ける、請求項67~73のいずれか一項に記載の方法。
- 前記患者が、3週ごとに3.6mg/kgの用量で14サイクルにわたりT-DM1を注入する治療を受ける、請求項67~74のいずれか一項に記載の方法。
- 前記治療が、トラスツズマブを用いるアジュバント治療と比較して、無浸潤疾患生存期間(IDFS)を実質的に増加させる、請求項67~75のいずれか一項に記載の方法。
- 前記治療が、トラスツズマブを用いるアジュバント治療と比較して、遠隔再発の減少をもたらす、請求項67~76のいずれか一項に記載の方法。
- 前記アジュバント療法が、トラスツズマブを用いるアジュバント療法と比較して、浸潤性疾患再発のリスクの50%低減をもたらす、請求項44~77のいずれか一項に記載の方法。
- 前記アジュバント療法が、アジュバントトラスツズマブと比較して、遠隔再発のリスクの40%低減をもたらす、請求項44~78のいずれか一項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023081595A JP2023113703A (ja) | 2018-10-15 | 2023-05-17 | トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862745914P | 2018-10-15 | 2018-10-15 | |
US62/745,914 | 2018-10-15 | ||
PCT/US2019/028953 WO2020081119A1 (en) | 2018-10-15 | 2019-04-24 | Methods of treating residual breast cancer with trastuzumab emtansine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023081595A Division JP2023113703A (ja) | 2018-10-15 | 2023-05-17 | トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022504866A true JP2022504866A (ja) | 2022-01-13 |
Family
ID=66998466
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021520348A Pending JP2022504866A (ja) | 2018-10-15 | 2019-04-24 | トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法 |
JP2023081595A Pending JP2023113703A (ja) | 2018-10-15 | 2023-05-17 | トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023081595A Pending JP2023113703A (ja) | 2018-10-15 | 2023-05-17 | トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法 |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP3856774B1 (ja) |
JP (2) | JP2022504866A (ja) |
KR (2) | KR20210076961A (ja) |
CN (1) | CN112867736A (ja) |
AU (2) | AU2019361871B2 (ja) |
CA (1) | CA3112836C (ja) |
DK (1) | DK3856774T3 (ja) |
ES (1) | ES2932432T3 (ja) |
FI (1) | FI3856774T3 (ja) |
HR (1) | HRP20221517T1 (ja) |
HU (1) | HUE060916T2 (ja) |
LT (1) | LT3856774T (ja) |
MX (3) | MX2021004145A (ja) |
PL (1) | PL3856774T3 (ja) |
PT (1) | PT3856774T (ja) |
RS (1) | RS63865B1 (ja) |
SG (1) | SG11202103148QA (ja) |
SI (1) | SI3856774T1 (ja) |
TW (1) | TWI820122B (ja) |
WO (1) | WO2020081119A1 (ja) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
ATE370961T1 (de) | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US7004206B2 (en) | 2004-01-29 | 2006-02-28 | Viken James P | Automatic fluid exchanger |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
KR20150043558A (ko) | 2004-07-22 | 2015-04-22 | 제넨테크, 인크. | Her2 항체 조성물 |
AR079256A1 (es) | 2009-12-04 | 2012-01-04 | Genentech Inc | Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1 |
WO2017087280A1 (en) * | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
EP3241562A1 (en) * | 2016-05-02 | 2017-11-08 | Fundació Institut Mar d'Investigacio Medica | Zonisamide for use in the treatment of breast cancer |
-
2019
- 2019-04-24 AU AU2019361871A patent/AU2019361871B2/en active Active
- 2019-04-24 EP EP19732147.4A patent/EP3856774B1/en active Active
- 2019-04-24 HU HUE19732147A patent/HUE060916T2/hu unknown
- 2019-04-24 MX MX2021004145A patent/MX2021004145A/es unknown
- 2019-04-24 DK DK19732147.4T patent/DK3856774T3/da active
- 2019-04-24 WO PCT/US2019/028953 patent/WO2020081119A1/en unknown
- 2019-04-24 PT PT197321474T patent/PT3856774T/pt unknown
- 2019-04-24 KR KR1020217014587A patent/KR20210076961A/ko active Application Filing
- 2019-04-24 KR KR1020247001570A patent/KR20240013844A/ko active Search and Examination
- 2019-04-24 FI FIEP19732147.4T patent/FI3856774T3/fi active
- 2019-04-24 EP EP22203622.0A patent/EP4227320A3/en active Pending
- 2019-04-24 CA CA3112836A patent/CA3112836C/en active Active
- 2019-04-24 CN CN201980067942.2A patent/CN112867736A/zh active Pending
- 2019-04-24 PL PL19732147.4T patent/PL3856774T3/pl unknown
- 2019-04-24 TW TW108114371A patent/TWI820122B/zh active
- 2019-04-24 RS RS20230002A patent/RS63865B1/sr unknown
- 2019-04-24 SG SG11202103148QA patent/SG11202103148QA/en unknown
- 2019-04-24 HR HRP20221517TT patent/HRP20221517T1/hr unknown
- 2019-04-24 JP JP2021520348A patent/JP2022504866A/ja active Pending
- 2019-04-24 ES ES19732147T patent/ES2932432T3/es active Active
- 2019-04-24 LT LTEPPCT/US2019/028953T patent/LT3856774T/lt unknown
- 2019-04-24 SI SI201930430T patent/SI3856774T1/sl unknown
-
2021
- 2021-04-09 MX MX2023006787A patent/MX2023006787A/es unknown
- 2021-04-09 MX MX2023004601A patent/MX2023004601A/es unknown
-
2023
- 2023-05-17 JP JP2023081595A patent/JP2023113703A/ja active Pending
- 2023-06-30 AU AU2023204220A patent/AU2023204220A1/en active Pending
Non-Patent Citations (3)
Title |
---|
"NCT01772472", CLINICALTRIALS.GOV ARCHIVE, vol. v135, JPN6022024939, July 2018 (2018-07-01), ISSN: 0004966160 * |
CRINICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 97, JPN6022024940, 2016, pages 96 - 106, ISSN: 0004966159 * |
JOURNAL OF CLINICAL ONCOLOGY, vol. 33, JPN6022024937, 2015, pages 1136 - 1142, ISSN: 0004966161 * |
Also Published As
Publication number | Publication date |
---|---|
MX2023004601A (es) | 2023-06-06 |
CA3112836C (en) | 2024-05-28 |
LT3856774T (lt) | 2023-03-10 |
KR20240013844A (ko) | 2024-01-30 |
TW202402328A (zh) | 2024-01-16 |
ES2932432T3 (es) | 2023-01-19 |
JP2023113703A (ja) | 2023-08-16 |
DK3856774T3 (da) | 2022-11-28 |
AU2019361871A1 (en) | 2021-04-15 |
EP3856774A1 (en) | 2021-08-04 |
EP3856774B1 (en) | 2022-11-02 |
CN112867736A (zh) | 2021-05-28 |
PL3856774T3 (pl) | 2023-03-06 |
HUE060916T2 (hu) | 2023-04-28 |
SI3856774T1 (sl) | 2023-02-28 |
TWI820122B (zh) | 2023-11-01 |
AU2019361871B2 (en) | 2023-08-10 |
EP4227320A3 (en) | 2023-09-13 |
TW202015737A (zh) | 2020-05-01 |
WO2020081119A1 (en) | 2020-04-23 |
CA3112836A1 (en) | 2020-04-23 |
MX2023006787A (es) | 2023-06-20 |
FI3856774T3 (fi) | 2023-01-13 |
KR20210076961A (ko) | 2021-06-24 |
EP4227320A2 (en) | 2023-08-16 |
HRP20221517T1 (hr) | 2023-02-17 |
MX2021004145A (es) | 2021-06-08 |
RS63865B1 (sr) | 2023-01-31 |
AU2023204220A1 (en) | 2023-07-20 |
SG11202103148QA (en) | 2021-04-29 |
PT3856774T (pt) | 2022-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220362379A1 (en) | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab | |
RU2725093C2 (ru) | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом | |
US20210040216A1 (en) | Methods of treating her2-positive cancer | |
KR20140009275A (ko) | 파클리탁셀 및 트라스투주맙-mcc-dm1에 의한 her2-양성 암의 치료 | |
US20150265723A1 (en) | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 | |
JP7330217B2 (ja) | Her2陽性転移性乳癌の治療方法 | |
JP2022504866A (ja) | トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法 | |
TWI848832B (zh) | 用曲妥珠單抗安坦辛治療殘存乳癌之方法 | |
US20200114018A1 (en) | Methods of treating residual breast cancer with trastuzumab emtansine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210610 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220920 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221221 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230117 |